Actimmune

GPTKB entity

Statements (60)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:approves gptkb:FDA
gptkbp:atccode L03 AB02
gptkbp:availability prescription only
gptkbp:brand gptkb:Actimmune
gptkbp:category gptkb:unknown
Category C
gptkbp:class biologic response modifier
gptkbp:clinical_trial Phase III
gptkbp:clinical_use gptkb:immunotherapy
gptkbp:code 00006-0001
gptkbp:contraindication hypersensitivity to interferon gamma-1b
gptkbp:dosage_form lyophilized powder for reconstitution
gptkbp:drug_interactions none reported
gptkbp:duration varies by condition
gptkbp:effective_date 1990-11-09
gptkbp:financial_stability expires after 24 hours at room temperature
https://www.w3.org/2000/01/rdf-schema#label Actimmune
gptkbp:indication treatment of infections
gptkbp:ingredients gptkb:interferon_gamma-1b
gptkbp:is_monitored_by liver function tests
complete blood count
renal function tests
gptkbp:lifespan approximately 2 hours
gptkbp:manufacturer gptkb:Inter_Mune,_Inc.
gptkbp:market conducted
gptkbp:marketed_as gptkb:Canada
gptkb:European_Union
gptkb:United_States
gptkbp:mechanism_of_action modulates immune response
gptkbp:packaging vial
gptkbp:patient_education storage requirements
importance of adherence to therapy
recognizing side effects
proper injection technique
when to seek medical attention
gptkbp:patient_population children and adults
provided with prescription
gptkbp:pharmacokinetics subcutaneous absorption
gptkbp:previous_name gptkb:interferon_gamma-1b
gptkbp:price varies by pharmacy
gptkbp:provides_guidance_on followed for administration
gptkbp:reconstitution_instructions dilute with sterile water
gptkbp:requires available
gptkbp:research ongoing
gptkbp:rounds renal
gptkbp:route_of_administration subcutaneous injection
gptkbp:safety_measures monitor for signs of infection
gptkbp:service_frequency 3 times a week
gptkbp:side_effect fatigue
headache
nausea
injection site reactions
autoimmune disorders
flu-like symptoms
gptkbp:storage refrigerated
gptkbp:used_for chronic granulomatous disease
severe malignant osteopetrosis
gptkbp:bfsParent gptkb:Horizon_Therapeutics
gptkbp:bfsLayer 5